10162831AI-Powered Computational Validation of Covalent Drug Discovery for Undruggable Cancer TargetsClosedFeasibility StudiesInnovate UKAxiom Therapeutics is addressing the challenge of designing drugs for cancer-causing proteins that have long been considered "undruggable". Many such proteins lack traditional binding pockets for drugs, but covalent inhibitors, drugs that form a permanent bond to their target, can overcome this limitation. Axiom's _TrueBond_ platform uses advanced artificial intelligence and quantum-mechanical modelling to predict how well a covalent drug will bind and permanently deactivate an "undruggable" cancer protein. In this project, we will test TrueBond's predictions in the lab. We will make several potential new drug molecules that TrueBond identified, then measure how strongly and permanently they attach to target proteins using mass spectrometry. By comparing the model's predictions to real-world results, we aim to prove that TrueBond can accurately forecast a covalent drug's effectiveness before it's made. If successful, this technology could significantly speed up the creation of new cancer treatments, giving researchers a powerful tool to tackle diseases that currently have few or no drug options.